AZD-1656

DB14810InvestigationalSmall molecule

AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).

Mechanism: Pharmacologically active on Hexokinase-4
Curator reviewed
Formula / weight: C₂₄H₂₆N₆O₅ · 478.509 g/mol (avg)
Code names: AZD-1656

Resolves to

Compound

UNII660M185X4DCAS919783-22-5ChEMBLCHEMBL3219124

Structure

InChIKeyFJEJHJINOKKDCW-INIZCTEOSA-NSMILESCOC[C@H](C)OC1=CC(=CC(OC2=NC=C(N=C2)C(=O)N2CCC2)=C1)C(=O)NC1=NC=C(C)N=C1

Targets

P35557GCK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with AZD-1656, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account